FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included

Stethoscope,Laying,On,Medicine,White,Pills,Money,With,Rx,Prescription

On Thursday, the U.S. Food and Drug Administration (FDA) announced six additional awardees under the Commissioner's National Priority Voucher (CNPV) pilot program.

• Boehringer Ingelheim Pharmaceuticals Inc.'s Hernexeos (Zongertinib) for HER2 lung cancer.
• Johnson & Johnson's (NYSE:JNJ) Sirturo (Bedaquiline) for drug-resistant tuberculosis in young children.
• GSK Plc's (NYSE:GSK) Jemperli (dostarlimab) for rectal cancer.
• Vertex Pharmaceuticals Inc.'s (NASDAQ:VRTX) Casgevy (exagamglogene autotemcel) for sickle cell disease
• Eli Lilly and Co.'s (NYSE:LLY) under development Orforglipron, an oral drug for obesity and related health conditions.
• Novo Nordisk A/S' (NYSE:NVO) Wegovy (semaglutide) for obesity and related health conditions.